Guides
Stem cell regulation in the European Union
EU cell-therapy regulation depends on the exact product, processing, intended function, indication and route of use. Clinic registration, trial registration and product authorisation are different decisions.
Some cell- and gene-based medicines are advanced therapy medicinal products (ATMPs). Their classification depends on facts such as substantial manipulation and whether cells perform the same essential function in donor and recipient. Do not infer classification from a marketing name such as stem cells, exosomes or regenerative therapy.
An ATMP supplied routinely in the EU generally requires a marketing authorisation for its specific product and indication. Check the EMA record and product information. An authorisation for one product, tissue or indication cannot be transferred to a different preparation or condition.
Investigational ATMPs may be administered in an authorised clinical trial. EU trials are handled under Regulation (EU) No 536/2014 through CTIS. The EMA CTIS page explains the public search and the information available. Trial authorisation permits research under a protocol; it is not marketing authorisation or proof of efficacy.
The hospital exemption is narrow. Article 28 of Regulation (EC) No 1394/2007 allows a Member State to authorise a custom-made ATMP prepared on a non-routine basis, used in a hospital in that same Member State under a medical practitioner's exclusive responsibility and made for an individual patient. National manufacturing authorisation, quality, traceability and pharmacovigilance requirements still apply. It is not a blanket exemption for a clinic, product catalogue or cross-border commercial programme.
Rules for donation, procurement, testing, processing, preservation, storage and distribution of human cells and tissues may also apply. Compliance with those rules does not by itself establish that a manufactured ATMP is authorised or clinically effective. The exact chain must be mapped product by product.
GMP addresses how an applicable medicinal product is manufactured and controlled. It does not prove that the product works, that its benefit outweighs risk, or that the proposed indication is authorised. Verify the manufacturing authorisation, site and product scope rather than accepting the phrase GMP-certified clinic.
The EMA and Heads of Medicines Agencies warn about unregulated ATMPs. Their patient check is practical: confirm an EMA authorisation, an authorised clinical trial or a valid national hospital exemption for the exact use. Marketing a product as experimental outside an authorised trial is a warning sign, not a regulatory route.
Before treatment, ask the national competent authority to confirm the provider, manufacturer, product and legal basis. Keep those four answers separate. Regulation reduces specified risks; it does not guarantee a favourable outcome for an individual patient.
Use the cost worksheet, then verify the exact product, evidence, legal route and written quotation with an independent qualified clinician.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.